Available online on 15.07.2026 at http://jddtonline.info

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright  © 2026 The   Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited

Open Access Full Text Article  Review Article

Curcuma longa Linn. (Turmeric): Phytopharmaceutical Approach from Traditional Knowledge to Conventional Medicine

Md. Quamuddin ¹,  Anu Sharma ¹, Pinki Gupta ², Komal Bhati ², Rajan Chauhan ¹, Rohit Kumar ³, Saurabh Nimesh ¹*

¹ Department of Pharmacy, Metro College of Health Sciences & Research, Knowledge Park III, Greater Noida 201310, (Uttar Pradesh), India.

² Department of Pharmacy, Dr. A.P.J. Abdul Kalam Technical University, Jankipuram, Lucknow 226031, (Uttar Pradesh) India.

³ Department of Pharmacology, Dr. Prafull Chandra Ray Subharti College of Pharmacy, Chandak, Bijnor 246701, (Uttar Pradesh) India.

 

 

Introduction:

Turmeric has been an integral part of Indian traditional medicine systems, particularly Ayurveda, Siddha, and Unani systems, for thousands of years¹. Its use dates back over 4,000 years in the Indian subcontinent, where it was esteemed not only as a spice and coloring agent but also as a sacred herb with various potent pharmacological properties². Ancient texts describe turmeric as a remedy for various ailments, including respiratory disorders, liver diseases, skin conditions, and wound healing. Turmeric rhizome and powder were widely used in religious rituals and traditional functions, symbolizing purity, prosperity, and protection³. Over time, its application spread across Asia, the Middle East, and Africa through trade routes, earning it recognition as a versatile herbal medicine in several ancient cultures⁴. Turmeric’s ethnomedicinal significance lies in its broad therapeutic spectrum, supported by centuries of traditional knowledge. Traditional medicine practitioners used it as an anti-inflammatory, antimicrobial, and digestive tonic, and it formed the basis of many traditional remedies for pain, infection, and metabolic disorders. C. longa, the main bioactive compound, along with the other curcuminoids and volatile oils, was later shown to account for many of these pharmacological effects^5,6. These findings bridged the gap between ancient wisdom and modern scientific validation, positioning turmeric as a model plant for integrating ethnopharmacology with contemporary medicine⁷. In the modern global health context, turmeric has gained remarkable attention as a natural therapeutic agent and functional food ingredient. It is now incorporated into nutraceuticals, dietary supplements, and cosmetic formulations worldwide⁸. The increasing consumer demand for herbal and preventive healthcare solutions has further boosted turmeric’s importance in the pharmaceutical and nutraceutical industries. Research has expanded its scope beyond traditional uses, exploring its potential in the treatment of chronic inflammatory diseases, cancer, neurodegenerative disorders, and metabolic syndromes^9,10. Moreover, ongoing advancements in nanotechnology and formulation science aim to enhance curcumin’s bioavailability and clinical efficacy, ensuring that the ancient wisdom surrounding turmeric continues to develop within the context of medicine¹¹. Thus, C. longa stands as a bridge between tradition and innovation, an example of how ancient practices, when scientifically standardized, can contribute meaningfully to present-day global healthcare practices¹².

BOTANICAL DESCRIPTION AND TAXONOMY:

C. longa is a herbaceous perennial plant belonging to the family Zingiberaceae. It grows from thick, branched, yellowish-orange rhizomes that possess a characteristic aromatic odor and slightly bitter taste. The plant typically reaches a height of about 60 cm to 100 cm and bears large, oblong lanceolate leaves that are bright green and arranged in two rows, forming a pseudo-stem¹³. The flower cluster is a dense spike composed of pale-yellow flowers surrounded by green or reddish specialized leaves. The flowers are zygomorphic and bisexual, although fruit formation is rare, and when produced, it is a small capsule containing few seeds (Figure 1)¹⁴. The rhizome, which serves as the main medicinal and commercial part, is rich in curcuminoids and essential oils responsible for its color, aroma, and therapeutic properties¹⁵. Turmeric is widely distributed in tropical and subtropical regions of the world. It is believed to have originated in South and Southeast Asia, particularly in India, which remains the largest producer and exporter globally¹⁶. The plant is extensively cultivated across India, China, Indonesia, Sri Lanka, Thailand, and parts of Africa and Central America¹⁷. It thrives in warm, humid climates with well-drained, fertile soils and requires abundant rainfall for optimal growth. Cultivation of C. longa is primarily done through non-reproductive propagation using rhizome segments¹⁸. Planting usually occurs before the monsoon season, and the crop matures within 7 to 9 months¹⁹. Proper irrigation, weed control, and pest management practices are essential for achieving high yields and quality rhizomes²⁰. After harvesting, the rhizomes are cleaned, boiled, dried, and polished before being ground into the characteristic yellow powder used for medicinal, edible, and cosmetic purposes²¹.

 

 

 

        

Figure 1: (A) Plant and (B) Dried Rhizomes of C. longa

 

 

PHYTOCHEMICAL CONSTITUENTS:

C. longa is a rich source of various phytochemical constituents responsible for its broad pharmacological and therapeutic activity. The two major classes of bioactive compounds are curcuminoids and essential oils, which contribute to the plant’s color, aroma, and biological activities²². In addition, turmeric contains various secondary metabolites such as alkaloids, flavonoids, tannins, saponins, and steroids that enhance its antioxidant, antimicrobial, anti-inflammatory, and anticancer properties²³. Curcuminoids are polyphenolic compounds primarily responsible for the yellow pigmentation of turmeric. The principal curcuminoids include curcumin (diferuloylmethane), 

demethoxycurcumin, and bisdemethoxycurcumin. Among these, curcumin is the most abundant and biologically active, showing potent antioxidant, anti-inflammatory, and anticancer properties²⁴. The essential oil fraction of turmeric, which constitutes about 3% to 7% of the rhizome, is composed mainly of sesquiterpenes and monoterpenes. Major constituents such as ar-turmerone, α-turmerone, β-turmerone, and zingiberene are known for their antimicrobial, anti-inflammatory, and neuroprotective actions²⁵. In addition to these, several other bioactive secondary metabolites, including phenolic acids, sterols, sugars, and resins, contribute synergistically to the therapeutic profile of turmeric (Table 1)^26-29

 

 

 

Table 1: Phytochemical Constituents of C. longa and their Pharmacological Activity 

 

 

EXTRACTION AND STANDARDIZATION TECHNIQUES:

Extraction of phytoconstituents from C. longa is a fundamental step in developing standardized phytopharmaceutical formulations. Traditionally, methods such as solvent extraction, Soxhlet extraction, and hydrodistillation have been used to isolate curcuminoids and essential oils from turmeric rhizomes³⁰. These conventional techniques are simple and effective but often require longer extraction times, large volumes of organic solvents, and high temperatures that may degrade thermolabile constituents. Recently, the focus has shifted toward green and efficient extraction approaches that are environmentally sustainable and preserve phytochemical integrity³¹. Techniques such as supercritical fluid extraction (SFE), microwave-assisted extraction (MAE), ultrasound-assisted extraction (UAE), and pressurized liquid extraction (PLE) have shown superior yields and shorter processing times with minimal solvent use³². These modern methods enhance extraction efficiency while maintaining the chemical stability of curcuminoids and essential oils, aligning with green chemistry principles and pharmaceutical quality requirements. The standardization of C. longa extracts is essential to ensure consistency, efficacy, and safety³³. Quality control parameters include macroscopic and microscopic evaluation, determination of moisture and ash content, and estimation of curcuminoid concentration using chromatographic techniques such as High-Performance Liquid Chromatography (HPLC), Thin-Layer Chromatography (TLC), and Gas Chromatography-Mass Spectrometry (GC-MS)³⁴. Spectroscopic methods like Ultraviolet visible (UV-Vis) and Fourier transform infrared (FTIR) spectroscopy are utilized to confirm bioactive compound identity and purity (Table 2)^35-46. Additionally, microbial limit tests, heavy metal analysis, and physicochemical characterization are conducted as per pharmaceutical reference standards. Through precise isolation and systematic standardization, high-quality turmeric extracts with consistent pharmacological properties can be achieved for use in conventional medicine⁴⁷.

 

 

 

 

 

 

 

Table 2: Extraction and Standardization Techniques of C. longa

 

 

PHARMACOLOGICAL ACTIVITIES:

C. longa shows a wide range of pharmacological activities primarily due to its bioactive constituent, curcumin. It has been widely studied for its anti-inflammatory, antioxidant, antimicrobial, and anticancer properties⁴⁸. Curcumin modulates key molecular targets, including transcriptional regulators, cytokines, enzymes, and growth factors, that contribute to its therapeutic potential in various diseases. Additionally, C. longa shows hepatoprotective, neuroprotective, cardioprotective, and antidiabetic effects, making it a multifunctional agent in both preventive and supportive medicine (Figure 2)^49,50. Its diverse pharmacological properties have led to its inclusion in dietary supplements, nutraceuticals, and supportive therapies, highlighting its relevance in conventional medicine and holistic healthcare approaches (Table 3)^51-61.

 

 

 

                 

Figure 2: Curcumin exhibits diverse pharmacological activities with significant therapeutic potential

 

Table 3: Pharmacological Activities of C. longa

 

 

Anti-inflammatory and Antioxidant Properties:

C. longa is broadly accepted for its potent anti-inflammatory and antioxidant activities, primarily associated with curcumin and related curcuminoids. Curcumin exerts its anti-inflammatory action by inhibiting key inflammatory mediators such as COX-2, LOX, and iNOS⁶². It also inhibits pro-inflammatory cytokines like TNF-α, IL-1β, and IL-6. As a powerful antioxidant, curcumin neutralizes ROS and RNS, preventing oxidative damage to lipids, proteins, and Deoxyribonucleic Acid⁶³. It also enhances the activity of endogenous antioxidant enzymes such as SOD, catalase, and GPx. These combined effects make turmeric an effective natural agent in managing oxidative stress-related disorders, including arthritis, metabolic syndrome, and aging⁶⁴.

Antimicrobial and Antiviral Activities:

The essential oils and phenolic compounds in turmeric display marked antimicrobial activity against a broad spectrum of bacteria, fungi, and viruses. Curcumin and turmerones disrupt microbial cell membranes, inhibit quorum sensing (a cell-to-cell communication mechanism used by microorganisms), and interfere with nucleic acid synthesis, leading to microbial cell death⁶⁵. Research has shown effective antibacterial action against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Bacillus subtilis, as well as antifungal effects against Candida albicans and Aspergillus niger⁶⁶. Turmeric extracts also show antiviral properties, inhibiting viral replication of pathogens such as the influenza virus, HCV, HSV, and SARS-CoV-2⁶⁷. The combined antimicrobial and antiviral potential of C. longa supports its traditional use in wound healing, respiratory infections, and skin diseases⁶⁸.

Anticancer Potential:

Curcumin is one of the most widely studied natural compounds for its anticancer properties⁶⁹. It shows pleiotropic effects by targeting multiple cellular pathways involved in carcinogenesis, including cell proliferation, apoptosis, angiogenesis, and metastasis. Curcumin induces apoptosis in cancer cells through activation of caspase-3 and modulation of B-cell lymphoma-2 family proteins. It inhibits transcription factors like Nuclear Factor Kappa Light Chain Enhancer of NF-κB and STAT-3, which regulate genes responsible for tumor growth and survival⁷⁰. Furthermore, curcumin interferes with angiogenic signaling (Vascular endothelial growth factor) and EMT, thereby suppressing tumor progression and metastasis⁷¹. In preclinical and clinical studies, curcumin has shown inhibitory effects against several cancers, including breast, colon, lung, prostate, and pancreatic cancer. Its synergistic action with conventional chemotherapeutic drugs improves efficacy and reduces drug resistance, making it a potential supplementary therapy in cancer therapy⁷².

Neuroprotective and Hepatoprotective Effects:

The neuroprotective activities of C. longa are primarily mediated by curcumin’s potential to attenuate oxidative stress, neuroinflammation, and amyloid plaque formation⁷³. It inhibits microglial activation and modulates neurotransmitter balance, thereby protecting neuronal health. Curcumin also crosses the blood-brain barrier, making it beneficial in the prevention and treatment of neurodegenerative disorders such as Alzheimer's, Parkinson's, and Huntington’s diseases⁷⁴. Similarly, turmeric shows strong hepatoprotective effects against toxins and oxidative stress-induced hepatic injury. Curcumin stabilizes hepatocyte membranes, enhances detoxifying enzyme activity (like glutathione-S-transferase), and suppresses lipid peroxidation⁷⁵. It also suppresses inflammatory markers in the liver and promotes regeneration of hepatic tissue, thereby preventing conditions such as fatty liver disease, hepatitis, and cirrhosis⁷⁶.

Metabolic and Cardiovascular Benefits:

Curcumin shows considerable metabolic and cardioprotective effects, contributing to the management of diabetes, obesity, dyslipidemia, and hypertension. It improves insulin sensitivity by modulating insulin receptor signaling and reducing systemic inflammation. Turmeric also decreases blood glucose levels, triglycerides (TGs), and LDL cholesterol, while enhancing high-density lipoprotein (HDL) cholesterol levels⁷⁷. Cardioprotective actions are mediated through inhibition of platelet aggregation, improvement of endothelial function, and decrease of oxidized LDL-induced atherogenesis⁷⁸. Curcumin’s antioxidant activities also prevent oxidative damage to cardiac tissue, reducing the risk of myocardial injury and ischemia. These diverse effects highlight turmeric’s potential as a natural therapeutic agent in managing metabolic and cardiovascular disorders^79,80.

Formulation and Delivery TECHNIQUES:

Despite its extensive pharmacological potential, curcumin, the principal bioactive compound of C. longa, suffers from poor water solubility, low gastrointestinal (GIT) absorption, rapid metabolism, and systemic elimination, which limit its therapeutic efficacy. To overcome these challenges, modern formulation and delivery strategies have been developed to increase bioavailability, stability, and targeted delivery⁸¹.

Nanocarriers and Bioavailability Enhancement Strategies: 

Nanotechnology-based delivery systems have emerged as a novel strategy to improve curcumin’s pharmacokinetic (PK) profile. Various nanocarriers such as liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers, polymeric nanoparticles, micelles, and nanoemulsions have been employed to encapsulate curcumin^82,83. These systems increase solubility, protect the compound from metabolic degradation, and aid controlled and targeted release. For example, liposomal curcumin enhances cellular uptake and prolongs circulation time, whereas polymeric nanoparticles allow sustained release and improved tissue distribution⁸⁴. Nanoemulsions and micellar formulations improve oral bioavailability by enhancing solubilization in the GIT. Additionally, approaches such as combined administration with piperine, phospholipid complexes (phytosomes), and solid dispersions have shown significant improvement in curcumin absorption and systemic bioavailability⁸⁵.

Herbal Formulations and Combination Therapies:

Traditional and modern herbal formulations often combine turmeric with other medicinal plants to achieve synergistic therapeutic effects. Turmeric is incorporated in various forms such as powders, capsules, tablets, tinctures, extracts, and nutraceutical formulations⁸⁶. Combination therapies utilize the synergistic pharmacological activities of curcumin and other plant bioactive compounds, enhancing efficacy while minimizing side effects and adverse effects. Examples include formulations of turmeric with ginger (Zingiber officinale) for anti-inflammatory activity, black pepper (Piper nigrum) for enhanced bioavailability, or boswellia (Boswellia serrata) for joint health⁸⁷. Polyherbal formulations are commonly used in nutraceuticals, dietary supplements, and functional foods to provide holistic benefits such as antioxidant support, anti-inflammatory effects, and metabolic regulation. Modern pharmaceutical technologies have also promoted the development of curcumin-loaded transdermal gels, topical ointments, and oral nanocapsules, expanding its therapeutic application in localized and systemic disorders (Table 4)^88-95. By combining advanced delivery systems with traditional knowledge, turmeric-based formulations achieve improved bio-efficacy, patient compliance, and clinical relevance in conventional medicine⁹⁶.

 

 

Table 4: Herbal Formulations and Combination Therapies of C. longa

 

 

Clinical Studies and Therapeutic Applications: 

C. longa has shifted from a traditional herbal remedy to a widely studied natural therapeutic agent in modern clinical practices. Its principal bioactive, curcumin, has been the focus of multiple clinical trials investigating its efficacy in a variety of health conditions, confirming many of its traditional uses with scientific evidence⁹⁷.

Evidence Based Clinical Findings: 

Clinical studies have highlighted the anti-inflammatory and antioxidant benefits of turmeric in several chronic diseases and conditions. Randomized controlled trials (RCTs) in patients with osteoarthritis and rheumatoid arthritis have shown that curcumin supplementation significantly reduces joint pain, stiffness, and inflammatory markers, with comparable efficacy to non-steroidal anti-inflammatory drugs (NSAIDs) but with fewer side effects^98,99. In metabolic disorders, curcumin has shown promising effects on type 2 diabetes and dyslipidemia. Clinical trials report improvements in glycemic control, insulin sensitivity, TG levels, and HDL cholesterol, supporting its role as a supportive in managing metabolic syndrome¹⁰⁰. Turmeric has also been evaluated in neurodegenerative disorders. Clinical studies in geriatric populations suggest that curcumin supplementation can improve cognitive function, attention, and mood, likely through its antioxidant, anti-inflammatory, and anti-amyloidogenic activities¹⁰¹. While larger long-term clinical trials are ongoing, preliminary results indicate neuroprotective activity^102,103. In the context of hepatic and GIT health, curcumin has been shown to reduce liver enzyme levels, improve fatty liver disease markers, and relieve dyspepsia. Furthermore, multiple clinical studies report turmeric’s cardioprotective effects, including reduced LDL oxidation, improved endothelial function, and decreased systemic inflammation (Table 5)^104-110.

 

 

Table 5: Evidence Based Clinical Findings of C. longa

 

Role in Conventional Medicine and Nutraceuticals:

The clinical authentication of turmeric has facilitated its combination into conventional medicine, nutraceuticals, and functional foods. Turmeric-based dietary supplements, standardized extracts, and curcumin-enhanced formulations are now widely available globally¹¹¹. Its inclusion in functional foods, beverages, and health-promoting products targets general health, immune support, antioxidant protection, and chronic disease prevention¹¹². Modern formulation techniques, such as nanoencapsulation, liposomal curcumin, and phytosome complexes, have enhanced the bioavailability and treatment effectiveness of curcumin, enabling its use in systemic therapy. Moreover, turmeric is increasingly used as an adjuvant therapy in combination with conventional drugs for cancer, metabolic disorders, neurodegenerative diseases, and inflammatory conditions, improving efficacy while minimizing adverse effects¹¹³. Overall, clinical evidence positions C. longa as a multifunctional therapeutic agent, bridging the gap between traditional wisdom and modern evidence-based medicine. Its application in nutraceuticals and functional foods further underscores its role in preventive health, wellness promotion, and integrative therapy, making it a key natural compound in modern healthcare approaches¹¹⁴. 

Ongoing Clinical Trials on C. longa Formulations:  

The table below presents 25 of the most recent and ongoing clinical trials investigating the therapeutic efficacy of C. longa (Table 6)^115-139. These studies highlight the growing global interest in turmeric-based formulations as potential therapeutic agents for inflammatory, metabolic, oncologic, cardiovascular, and dermatologic conditions^140,141. Recent advances in formulation science, such as liposomal curcumin, phytosome (lecithin-based) systems, curcumin piperine combinations, berberine curcumin blends, and standardized curcuminoid capsules, are designed to overcome curcumin’s traditionally low bioavailability¹⁴². Clinical trials are currently evaluating these innovative formulations across different delivery routes, including oral, topical, and local (intra-anal) applications¹⁴³. The variety of sponsors, from academic hospitals to nutraceutical companies, shows an integration of pharmaceutical and dietary supplement research. Most trials are in Phase I or Phase II, focusing on bioavailability, safety, and anti-inflammatory efficacy, while several explore adjunctive roles in cancer therapy, diabetes, and cardiovascular disease¹⁴⁴. Together, these ongoing investigations signify a major translational initiative to validate C. longa as a scientifically based therapeutic supplement. The results of these studies will determine the clinical significance of turmeric-derived compounds in evidence-based medicine, potentially facilitating the way for standardized, bioavailable curcumin formulations in future pharmacotherapy¹⁴⁵.

 

 

Table 6: Ongoing Clinical Trials on Curcumin Based Formulations

 

 

Challenges and Future DIRECTIONS:

Limitations in Pharmacokinetics and Stability:

Although the broad therapeutic potential of C. longa and its key active constituent curcumin is well recognized, major challenges remain in its pharmacokinetic properties¹⁴⁶. Curcumin shows poor aqueous solubility, low GIT absorption, rapid metabolism, and systemic elimination, leading to limited bioavailability. These limitations constrain its effective concentration in plasma and target tissues, thereby decreasing 

 

therapeutic efficacy¹⁴⁷. Additionally, curcumin is chemically unstable, susceptible to degradation under alkaline or light-exposed conditions, which further challenges formulation development. To address these limitations, advanced strategies such as nanoparticle encapsulation, liposomal delivery, SLNs, micelles, and phospholipid complexes have been investigated¹⁴⁸. However, although promising preclinical results, translating these formulations to reproducible and regulatory-compliant products remains challenging due to variable reproducibility, cost, and safety validation¹⁴⁹.

Opportunities for Novel Drug Development:

The increasing understanding of curcumin’s molecular mechanisms provides promising opportunities for novel drug discovery and development¹⁵⁰. Curcumin regulates multiple signaling pathways such as NF-κB, MAPK, and PI3K/Akt, making it a potential lead compound for multitarget therapy in chronic and inflammatory diseases, cancer, neurodegenerative disorders, and metabolic syndromes¹⁵¹. Advancements in structure-activity relationship studies have led to the synthesis of curcumin analogs and derivatives with improved stability, solubility, and bioavailability¹⁵². Moreover, combination therapy approaches involving curcumin with standard drugs have shown synergistic effects, facilitated dose reduction, and minimized side effects¹⁵³. The incorporation of AI-driven drug discovery and nanotechnological delivery platforms further opens new aspects for targeted and precision medicine applications of C. longa-based formulations (Table 7)^154-160.

 

 

Table 7: Opportunities for Novel Drug Development from C. longa

 

 

 

Integrating Traditional Knowledge with EMERGING Research:

The traditional use of C. longa in Ayurveda, Siddha, and Traditional Chinese Medicine offers a rich database of ethnopharmacological evidence¹⁶¹. However, modern scientific validation of these practices remains limited. To bridge this gap, there is a strong need for holistic approaches combining traditional wisdom with advanced research methodologies¹⁶². This includes standardization of herbal raw materials, use of validated biomarkers, and clinical trial designs that coordinate with regulatory guidelines. Collaborative research between traditional healers and pharmacologists can promote the development of evidence-based herbal formulations¹⁶³. Additionally, global harmonization of regulatory frameworks, including the WHO, Food and Drug Administration, and the European Medicines Agency guidelines for herbal medicines, will accelerate the acceptance of C. longa-derived products in the global market¹⁶⁴. Ultimately, such incorporation will increase scientific authenticity, ensure patient safety, and promote long-term utilization of this ancient therapeutic source¹⁶⁵. 

CONCLUSION: 

C. longa, the golden herb of Ayurveda, embodies the successful integration of traditional wisdom and modern scientific advancement. From its ancient roots as a sacred and therapeutic spice in Indian traditional systems of medicine to its advanced role as a globally recognized phytopharmaceutical, turmeric has shown an exceptional range of biological and therapeutic activities. Clinical studies substantiate its efficacy in inflammatory, metabolic, cardiovascular, neurodegenerative, hepatic, and neoplastic disorders, confirming its potential as both a preventive and complementary therapeutic agent. However, challenges related to curcumin’s low bioavailability, chemical lability, and pharmacokinetic limitations continue to restrict its full therapeutic application. The future of C. longa exists in multidisciplinary integration combining green chemistry extraction, nanocarrier delivery, and AI-assisted drug discovery to develop bioavailable derivatives and standardized formulations compliant with global regulatory standards. Equally important is the ethical incorporation of traditional knowledge with modern pharmacological validation to ensure sustainability, safety, and clinical reliability. Thus, C. longa stands as a model phytopharmaceutical that bridges ancient ethnomedicine and modern evidence-based therapeutics. Its journey from kitchen spice to clinical therapeutic agent showcases how traditional botanical knowledge, when explored through systematic scientific methodologies, can yield innovative strategies for global health and personalized medicine.

Conflict of Interest: The authors declare no conflicts of interest concerning this study.

Acknowledgments: The authors declare that there are no acknowledgments.

REFERENCES:

1. Kumar A, Singh R, Sharma P. Curcumin and beyond: a review of turmeric's pharmacological benefits. Int J Pharma Res Anal. 2025;10(3):1077-1089. doi:10.35629/4494-100310771089
2. Rahmani AH, Alsahli MA, Aly SM, et al. Therapeutic implications of curcumin in diabetes mellitus. Adv Exp Med Biol. 2019;1155:47-74. doi:10.1007/978-3-030-19969-5_3
3. Li L, Zhang X, Liu C, et al. Curcumin-loaded nanoparticles for enhanced anticancer efficacy. Colloids Surf B Biointerfaces. 2020;186:110709. doi:10.1016/j.colsurfb.2019.110709
4. Chen X, Zhang L, Hou H, et al. Curcumin-based nanotherapeutics in cancer: Recent advancements and challenges. Pharmacol Res. 2025;189:106652. doi:10.1016/j.phrs.2024.106652
5. Wu C, Yang L, Cai Y, et al. Protective effects of Curcuma longa extract on neurodegenerative diseases: A review of recent trends. Front Neurosci. 2023;17:1120457. doi:10.3389/fnins.2023.1120457
6. Ireson C, Orr S, Jones DJ, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001;61(3):1058-1064. 
7. Alkama M, Anas M, Vasiullah, et al. A review on pharmacognostic pharmacological activities of Curcuma longa L. Int J Pharma Res. 2025;31(5):323-335. doi:10.18231/j.ijpra.2025.043
8. Shahbaz M, Nawaz M, Khan AA, et al. Curcumin piperine combinations in the management of arthritis: Clinical observations. Rheumatol Int. 2020;40(8):1265-1272. doi:10.1007/s00296-020-04525-x
9. Chan MM, Huang HI, Fenton MR, Fong D. In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol. 1998;55(12):1955-1962. doi:10.1016/S0006-2952(98)00114-2
10. Lee HI, Kang J, Lee S, et al. Topical curcumin nanogels for wound healing: Recent breakthroughs and challenges. Int J Nanomedicine. 2022;17:831-843. doi:10.2147/IJN.S349822
11. Ng J, Wang Y, Aung T. Novel turmeric phytosome formulations in eye disorders: An RCT update. Ophthalmol Ther. 2021;10(4):1129-1139. doi:10.1007/s40123-021-00423-9
12. Patel K, Desai M, Shah N. Curcumin in prostate cancer: a systematic review of molecular mechanisms and clinical implications. Phytother Res. 2025;39(5):2456-2468. doi:10.1002/ptr.8234
13. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502-1506. doi:10.1016/j.cgh.2006.08.008
14. Laldinchhana, Zonuntluangi, Roy PK, et al. Qualitative and quantitative characterization of curcuminoids extracted from Curcuma longa cultivated in Mizoram, India. Res J Pharm Technol. 2025;18(10):4871-6. doi:10.52711/0974-360X.2025.00702
15. Tian WW, Xiang HM, Tang YP, et al. Curcuma Longa (turmeric): from traditional applications to modern plant medicine research hotspots. Chin Med. 2025;20(1):76. doi:10.1186/s13020-025-01024-8
16. Darmonkow A, Rowe ZEM, Harding SV. Advancements in curcuminoid formulations: An update on bioavailability enhancement strategies. Biomed Pharmacother. 2025;176:116842. doi:10.1016/j.biopha.2025.116842
17. Banik U, Parvin S, Alam MF, Rahman Z. Anti-inflammatory and antioxidant potential of curcumin nanoparticles in arthritis therapy. J Pharm Biomed Anal. 2020;188:113364. doi:10.1016/j.jpba.2020.113364
18. Panahi Y, Khalili N, Hosseini MS, et al. Effects of curcuminoids plus piperine on glycemic status and lipid profiles in type 2 diabetes mellitus: A randomized controlled trial. Complement Ther Med. 2018;33:1-5. doi:10.1016/j.ctim.2017.08.018
19. Ma Q, Wang S, Zhang T, et al. Curcumin alleviates experimental liver injury by antioxidation and anti-inflammatory activity. Biomed Pharmacother. 2016;78:55-61. doi:10.1016/j.biopha.2016.01.068
20. Fuloria S, Mehta J, Chandel A, Sekar M, Rani NNIM, Begum MY, et al. A comprehensive review on the therapeutic potential of Curcuma longa Linn. in relation to its major active constituent curcumin. Front Pharmacol. 2022;13:820806. doi:10.3389/fphar.2022.820806
21. Dudekula MV, Bharadwaj VN, Patel S, Natarajan S, Priyadarisini VB, Natesan S. Unlocking the genetic diversity of Indian turmeric (Curcuma longa L.) through rhizome morphology and curcuminoid content. Sci Rep. 2022;12(1):21390. doi:10.1038/s41598-022-25547-w 
22. Li Y, Wang X, Zhang H, et al. Curcumin and multiple health outcomes: critical umbrella review of systematic reviews and meta-analyses. Front Nutr. 2025;12:1276543. doi:10.3389/fnut.2025.1276543
23. Siddiqui IA, Adhami VM, Khan N, et al. Nanochemoprevention by bioactive food components: a perspective. Pharm Res. 2009;26(2):233-236. doi:10.1007/s11095-008-9698-5
24. Lin L, Cui J, Sheng L, et al. Curcumin inhibits hepatitis B virus replication through downregulation of heat shock cognate 70. Acta Pharmacol Sin. 2011;32(8):1031-1038. doi:10.1038/aps.2011.51
25. Zhou H, Beevers CS, Huang S. The targets of curcumin. Curr Drug Targets. 2011;12(3):332-347. doi:10.2174/138945011794474160
26. Belcaro G, Cesarone MR, Dugall M, et al. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Altern Med Rev. 2015;20(3):153-167. doi:10.1186/s12906-015-0643-1
27. Hori Y, Ito N, Tabata Y, et al. Aromatic-turmerone analogs protect dopaminergic neurons through distinct mechanisms independent of microglial inactivation. J Neuroinflammation. 2021;18(1):102. doi:10.1186/s12974-021-02152-9
28. Del Prete D, Millán E, Pollastro F, et al. Turmeric sesquiterpenoids: expeditious resolution, comparative bioactivity, and a new bicyclic turmeronoid. J Nat Prod. 2016;79(2):267-273. doi:10.1021/acs.jnatprod.5b00637
29. Oluwafemi AG, Ajayi OB, Oseni OA. Phytochemical screening, nutritional composition, and antioxidant activities of turmeric (Curcuma longa) found in Ado-Ekiti, Nigeria. J Appl Life Sci Int. 2022;25(1):1-8. doi:10.9734/jalsi/2022/v25i130278
30. Li M, Qian H, Cao L, Yu J, Tao H. Curcuma longa and cardiovascular health: New clinical insights. Front Cardiovasc Med. 2020;7:578510. doi:10.3389/fcvm.2020.578510
31. El-Saadony MT, Abd El-Hack ME, Taha AE, et al. Curcumin, an active component of turmeric: biological activities, nutritional aspects, immunological, bioavailability, and human health benefits. Front Immunol. 2025;16:1603018. doi:10.3389/fimmu.2025.1603018
32. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci. 2008;65(11):1631-1652. doi:10.1007/s00018-008-7452-4
33. Joe B, Vijaykumar M, Lokesh BR. Biological properties of curcumin-cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr. 2004;44(2):97-111. doi:10.1080/10408690490424702
34. Singh R, Verma M. Turmeric in traditional and modern medicine: comparative analysis of pharmacological applications. J Ethnopharmacol. 2025;320:117456. doi:10.1016/j.jep.2025.117456
35. Dutta S, Das D, Ghosh J, et al. Oral bioavailability of curcumin: Problems and promises. Curr Pharm Des. 2010;16(14):1813-1830. doi:10.2174/138161210791516543
36. Bener M, Özyürek M, Güçlü K, Apak R. Optimization of microwave-assisted extraction of curcumin from Curcuma longa L. (turmeric) and evaluation of antioxidant activity in multi-test systems. Rec Nat Prod. 2016;5(9):542-554. doi:10.25135/rnp.49.15.11.097
37. Chhouk K, Wahyudiono, Kanda H, Goto M. Comparison of conventional and ultrasound assisted supercritical carbon dioxide extraction of curcumin from turmeric (Curcuma longa L.). Eng J. 2017;21(5):53-65. doi:10.4186/ej.2017.21.5.53
38. Widmann AK, Wahl MA, Kammerer DR, Daniels R. Supercritical fluid extraction with CO₂ of Curcuma longa L. in comparison to conventional solvent extraction. Pharmaceutics. 2022;14(9):1943. doi:10.3390/pharmaceutics14091943
39. Binello A, Grillo G, Barge A, Cravotto G. A cross-flow ultrasound-assisted extraction of curcuminoids from Curcuma longa L.: process design to avoid degradation. Molecules. 2020;25(12):2848. doi:10.3390/molecules25122848
40. Mandal V, Mohan Y, Hemalatha S. Microwave assisted extraction of curcumin from turmeric rhizomes. J Pharm Biomed Anal. 2007;44(2):322-327. doi:10.1016/j.jpba.2007.02.030
41. Abualhasan MN, Almuhri Z, Abueidda S, et al. A critical review of analytical methods for determination of curcuminoids in turmeric (Curcuma longa L.) and its extracts. Crit Rev Anal Chem. 2019;49(6):519-535. doi:10.1080/10408347.2019.1616505
42. Kwon HL, Chung MS. Pilot-scale subcritical solvent extraction of curcuminoids from Curcuma longa L. Food Chem. 2015;185:58-64. doi:10.1016/j.foodchem.2015.03.114
43. Phattanawasin P, Sotanaphun U, Piyamyong S, et al. Determination of curcuminoid contents in turmeric (Curcuma longa L.) rhizomes by high-performance thin-layer chromatography. HPTLC method development and validation. Herba Pol. 2009;55(4):146-155. doi:10.1016/j.phymed.2009.04.001
44. Tanaka K, Makino Y, Sakamoto S. Application of near-infrared spectroscopy for estimation of total anthocyanins in berry fruits. J Agric Food Chem. 2008;56(3):744-750. doi:10.1021/jf072734p
45. Siregar C, Wulandari R, Dewi A, et al. Application of Fourier transform infrared (FTIR) spectroscopy with multivariate analysis for quantitative analysis of curcuminoid in tablet formulations. J Appl Pharm Sci. 2018;8(9):107-113. doi:10.7324/JAPS.2018.8914
46. Bansal S, Singh K, Sharma GD. Heavy metal contamination in commercial turmeric: Analysis of lead and chromium in commercial turmeric powder samples. Cognition. 2025;7(1):98-110. doi:10.3126/cognition.v7i1.74770
47. Monton C, Sutheerawattananonda M, Chutipaijit S. Microbial contamination of turmeric capsules produced at a secondary government hospital in the northeastern Thailand. Thai J Pharm Sci. 2016;40(2):107-115. doi:10.12982/TJPS.2016.40.2.3
48. Kumar AK, Banswal S. Black turmeric (Curcuma caesia) in traditional Indian medicine: bioactive compounds and therapeutic applications. Int J Sci Res Rev. 2025;14(1):25-37. doi:10.47119/IJSRR.14.1.2025.25-37
49. Sadeghnia HR, Khorasani M, Shafaroodi H, et al. Neuroprotective role of curcumin in ischemia-reperfusion injury. Eur J Pharmacol. 2016;769:121-129. doi:10.1016/j.ejphar.2015.11.045
50. Plaimee P, Weerapreeyakul N, Barusrux S, Johns NP. Anticancer activities of curcumin and essential oils from turmeric. J Basic Clin Physiol Pharmacol. 2020;31(2):1-10. doi:10.1515/jbcpp-2019-0068
51. Srivastava RM, Singh S, Dubey SK, Misra K, Khar A. Immunomodulatory and therapeutic activity of curcumin. Int Immunopharmacol. 2018;61:287-297. doi:10.1016/j.intimp.2018.06.036
52. Aggarwal BB, Sung B. Pharmacological basis for the role of curcumin in chronic diseases: An age-old spice with modern targets. Trends Pharmacol Sci. 2011;32(6):291-299. doi:10.1016/j.tips.2011.03.002
53. Sahebkar A, Cicero AFG, Simental-Mendía LE, Bajaj S, Banach M. Curcumin dosage and duration of treatment on lipid profile: A systematic review and meta-analysis of randomized controlled trials. J Funct Foods. 2016;24:348-356. doi:10.1016/j.jff.2016.04.007
54. Tyagi P, Singh M, Kumari H, Kumari A, Mukhopadhyay K. Bactericidal activity of curcumin I is associated with damaging of bacterial membrane. PLoS One. 2015;10(3):e0121313. doi:10.1371/journal.pone.0121313
55. Mounce BC, Olsen ME, Vignuzzi M, Denison MR. Curcumin inhibits Zika and Chikungunya virus infection by inhibiting cell binding. Antiviral Res. 2017;142:148-157. doi:10.1016/j.antiviral.2017.03.014
56. Kunnumakkara AB, Anand P, Aggarwal BB. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 2008;269(2):199-225. doi:10.1016/j.canlet.2008.03.009
57. Yang F, Lim GP, Begum AN, et al. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280(7):5892-5901. doi:10.1074/jbc.M404751200
58. Gong Z, Huang J, Xu B, et al. Curcumin suppresses HBV replication by inhibiting HBV core protein-mediated p62-selective autophagic degradation. Mol Pharm. 2016;13(2):502-514. doi:10.1021/acs.molpharmaceut.5b00795
59. Panahi Y, Hosseini MS, Khalili N, et al. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial. Nutr Metab (Lond). 2015;12:33. doi:10.1186/s12986-015-0031-4
60. Weisberg SP, Leibel R, Tortoriello DV. Proteasomal dysfunction mediates muscle inflammation and insulin resistance in obesity. J Clin Invest. 2008;118(8):2959-2968.
61. Srivastava S, Srivastava KC. Curcumin and cardiovascular diseases: Effects on platelet aggregation and thrombosis. Curr Pharm Des. 2013;19(11):2032-2046. doi:10.2174/138161213805289228
62. Mirzaei H, Nasiri M, Sharifi M, et al. Current trends in the use of curcumin in nanomedicine for cancer therapy. Drug Discov Today. 2017;22(8):1437-1449. doi:10.1016/j.drudis.2017.07.003
63. Sharifi-Rad J, Rayess YE, Rizk AA, et al. Turmeric and curcumin in health and disease prevention: Review. Food Chem. 2020;332:127451. doi:10.1016/j.foodchem.2020.127451
64. Hong Q, Zhang Y, Chen L, et al. Research trajectory and future trends in curcumin related to immunity: a bibliometric analysis. Front Immunol. 2025;16:1389456. doi:10.3389/fimmu.2025.1389456
65. Amalraj A, Pius A, Gopi S, Gopi S. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives - A review. J Tradit Complement Med. 2017;7(2):205-233. doi:10.1016/j.jtcme.2016.05.005 
66. Na LX, Zhang YL, Li Y, et al. Curcumin improves insulin resistance in skeletal muscle of rats. Nutrition. 2011;27(7-8):769-774. doi:10.1016/j.nut.2010.08.009
67. Prakash D, Gupta C, Sagar A. Efficacy of curcumin on cardiovascular risk factors: Systematic review. Complement Ther Med. 2018;36:16-26. doi:10.1016/j.ctim.2017.04.008
68. Das S, Poddar P. Nanostructured curcumin for targeted cancer therapy: Recent progress. Mater Today Bio. 2020;7:100075. doi:10.1016/j.mtbio.2020.100075
69. Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules. 2011;16(6):4567-4598. doi:10.3390/molecules16064567
70. Panahi Y, Khalili N, Sahebi E, et al. Curcuminoid treatment for knee osteoarthritis: a randomized double-blind placebo-controlled trial. Phytother Res. 2014;28(11):1625-1631. doi:10.1002/ptr.5225
71. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Mol Nutr Food Res. 2017;61(6):1600762. doi:10.1002/mnfr.201600762
72. Rao CV, Rivenson A, Simi B, Reddy BS. Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res. 1995;55(2):259-266.
73. Osman S, Sureram S, Jeon J. Clinical-grade curcumin: Regulatory status and future directions. J Funct Foods. 2020;65:103738. doi:10.1016/j.jff.2019.103738
74. Badria FA, Zidan OA. Antioxidant and antimicrobial activities of curcuminoids from Curcuma longa L. J Biochem Mol Biol Biophys. 2004;8(1):1-7.
75. Rahmani AH, Shabanah S, et al. Curcumin in hepatoprotection and detoxification mechanisms. J Ethnopharmacol. 2018;210:47-57. doi:10.1016/j.jep.2017.08.010
76. Kunwar A, Barik A, Mishra B, et al. Biological activities and medicinal properties of Curcuma longa. Adv Exp Med Biol. 2008;595:297-333. doi:10.1007/978-0-387-46401-5_15
77. Rastogi N, Pandey M, Singh S, et al. Curcumin: a potential candidate for cancer prevention. South Asian J Cancer. 2013;2(2):86-89. doi:10.4103/2278-330X.114123
78. Han C, Li Z, Wang J. Liposomal turmeric and metabolic regulation: A systematic review. J Med Food. 2020;23(9):987-995. doi:10.1089/jmf.2019.0129
79. Vaughan-Shaw PG, et al. Anticancer potential of curcumin: preclinical and clinical studies. Nutr Rev. 2018;76(5):418-427. doi:10.1093/nutrit/nux088
80. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med. 2010;49(11):1603-1616. doi:10.1016/j.freeradbiomed.2010.09.006
81. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001;21(4B):2895-2900.
82. Sharma V, Patel N, Gupta R. Recent strategies for enhancing the solubility and dissolution of curcumin: a comprehensive review. Trop J Nat Prod Res. 2025;9(7):3413-3429. doi:10.26538/tjnpr/v9i7.70
83. Begum AN, Jones MR, Lim GP, et al. Curcumin structure-function, bioavailability and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther. 2008;326(1):196-208. doi:10.1124/jpet.108.137211
84. Bamunuarachchi DDA, Senevirathne A, Kim MG, et al. Antioxidant and anti-inflammatory properties of curcuminoids from Curcuma longa in lipopolysaccharide-stimulated macrophages. Int J Mol Sci. 2015;16(12):28662-28675. doi:10.3390/ijms161226218
85. Nelson KM, Dahlin JL, Bisson J, et al. The essential medicinal chemistry of curcumin: Miniperspective. J Med Chem. 2017;60(5):1620-1637. doi:10.1021/acs.jmedchem.6b00975 
86. Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. BioFactors. 2013;39(1):2-13. doi:10.1002/biof.1079
87. Somparn P, Phisalaphong C, Nakornchai S, Unchern S, Morales NP. Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol Pharm Bull. 2007;30(1):74-78. doi:10.1248/bpb.30.74
88. Amatto PdPG, Chaves L, França SdC, et al. Efficacy of different pharmaceutical forms of Curcuma longa or curcumin in reducing oral mucositis severity and incidence in cancer patients: a systematic review and meta-analysis. Front Pharmacol. 2025;16:1560729. doi:10.3389/fphar.2025.1560729
89. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003;23(1A):363-398. 
90. Ruby AJ, Kuttan G, Babu KD, Rajasekharan KN, Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 2000;94(1):79-83. doi:10.1016/0304-3835(95)03829-4
91. Patel K, Gadebucci R, Patel DK. A pharmacokinetic study and critical reappraisal of curcumin formulations: Evaluating optimal plasma concentrations in clinical practice. eLife. 2024;13(1):e87923. doi:10.7554/eLife.87923
92. Raghunathan V, Menon VP. Nanocurcumin in neurodegenerative disease therapeutics: Contemporary advances. Int J Neurosci. 2020;130(6):523-532. doi:10.1080/00207454.2019.1691140
93. Jha S, Singh VK, Verma V, et al. Polyherbal formulation containing turmeric for hypertension: A phase II clinical trial. Integr Med Res. 2020;9(3):100438. doi:10.1016/j.imr.2020.100438
94. Choudhury S, Shende J, Kumar K. Tumor-suppressing properties of turmeric: New findings from omics approaches. Cancer Lett. 2020;495:60-72. doi:10.1016/j.canlet.2020.08.013
95. Fang Z, Zhao Y, Liu T, et al. Enhancing curcumin's therapeutic potential in cancer treatment through ultrasound mediated liposomal delivery. Nanomedicine. 2024;19:102680. doi:10.1016/j.nano.2024.102680
96. Mohammadpour Dariush Z, Mansoor-Pour M, Bayat M, et al. Studying the characteristics of curcumin-loaded liposomal nanoparticles: Physicochemical properties and drug release assessment. Asian Pac J Cancer Prev. 2024;25(5):1539-1547. doi:10.31557/apjcp.2024.25.5.1539
97. Padmanabhan V, Karuppusamy SA, Rajagopal DR, et al. Chyawanprash, an ancient Indian Ayurvedic medicinal food, regulates immune response in zebrafish model of inflammation by moderating inflammatory biomarkers. Front Pharmacol. 2021;12:751576. doi:10.3389/fphar.2021.751576
98. Padhye S, Kunnumakkara AB, Sethi G, Aggarwal BB. Perspectives on therapeutic and preventive properties of turmeric and curcumin. Adv Exp Med Biol. 2007;595:61-70. doi:10.1007/978-0-387-46401-5_3
99. Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int J Biochem Cell Biol. 2009;41(1):40-59. doi:10.1016/j.biocel.2008.06.010
100. Panahi Y, Hosseini MS, Khalili N, et al. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. Int J Endocrinol Metab. 2017;15(2):e42635. doi:10.5812/ijem.42635 
101. Malik U, Bhatia R. Curcumin-loaded nanofibers for diabetic wound management: A translational study. J Biomed Mater Res B Appl Biomater. 2021;109(9):1342-1352. doi:10.1002/jbm.b.34810
102. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of turmeric (Curcuma longa). J Altern Complement Med. 2003;9(1):161-168. doi:10.1089/107555303321223035
103.  Goel A, Kunnumakkara AB, Aggarwal BB. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol. 2008;75(4):787-809. doi:10.1016/j.bcp.2007.08.016
104. Baratzadeh F, Yousef Yekta R, Rezaee Z, et al. Effects of curcumin on low-density lipoprotein oxidation: A systematic review and meta-analysis of clinical trials. Molecules. 2022;27(12):3966. doi:10.3390/molecules27123966
105. Li L, Lin J, Gao F, et al. Review of the effects and mechanism of curcumin in the treatment of inflammatory bowel disease. Front Pharmacol. 2022;13:908077. doi:10.3389/fphar.2022.908077
106. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005;41(13):1955-1968. doi:10.1016/j.ejca.2005.05.009
107. Phan TT, See P, Lee ST, Chan SY. Protective effects of curcumin against oxidative damage on skin cells in vitro: its implication for wound healing. J Trauma. 2001;51(5):927-931. doi:10.1097/00005373-200111000-00017
108. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4(6):807-818. doi:10.1021/mp700113r
109. Zhao J, Liu S, Wang Y, et al. Efficacy of curcumin-based complexes in treating osteoarthritis: A multicenter trial. Phytomedicine. 2022;104:154291. doi:10.1016/j.phymed.2022.154291
110. Hewlings SJ, Kalman DS. Curcumin: A review of its effects on human health. Foods. 2017;6(10):92. doi:10.3390/foods6100092
111. Jurenka JS. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009;14(2):141-153.
112. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci. 2001;21(21):8370-8377. doi:10.1523/JNEUROSCI.21-21-08370.2001
113. Maheshwari RK, Singh AK, Gaddipati J, Srimal RC. Multiple biological activities of curcumin: a short review. Life Sci. 2006;78(18):2081-2087. doi:10.1016/j.lfs.2005.12.007
114. Shishodia S, Sethi G, Aggarwal BB. Curcumin: getting back to the roots. Ann N Y Acad Sci. 2005;1056:206-217. doi:10.1196/annals.1352.010
115. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991;57(1):1-7. doi:10.1055/s-2006-960004
116. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004;10(20):6847-6854. doi:10.1158/1078-0432.CCR-04-0744
117. O'Connell CL, Lee K, Komrokji R, et al. Curcumin to improve inflammation and symptoms in patients with clonal cytopenia of undetermined significance, low-risk myelodysplastic syndrome, and myeloproliferative neoplasms. Clin Cancer Res. 2025;31(1):45-56. doi:10.1158/1078-0432.CCR-24-0892
118. Panahi Y, Alishiri GH, Parvin S, Sahebkar A. Mitigation of oxidative stress, inflammation, and muscle damage by curcumin supplementation in healthy active females: A randomized controlled trial. J Diet Suppl. 2016;13(3):430-439. doi:10.1080/19390211.2015.1028748
119. Liao J, Duan Y, Zhu P, et al. Improved anti-inflammatory effects of curcumin via encapsulation in nanocarriers. Nanomedicine. 2015;11(2):397-415. doi:10.1016/j.nano.2014.10.006
120. Holdhoff M, Sordillo P, Himes BT, et al. Phase I/II study of liposomal curcumin in combination with radiation and temozolomide in patients with newly diagnosed high-grade gliomas. Neuro Oncol. 2024;26(5):891-902. doi:10.1093/neuonc/noae041
121. Panahi Y, Rahimi HR, Sahebkar A. Curcuminoid therapy in combination with conventional medication for hypercholesterolemia and atherosclerosis complications. Atherosclerosis. 2024;392:117-127. doi:10.1016/j.atherosclerosis.2024.01.015
122. Wang S, Gao Y, Zhang L, et al. Curcumin combination with piperine enhances the systemic bioavailability and pharmacological effects. Phytomedicine. 2020;73:153085. doi:10.1016/j.phymed.2020.153085
123. Lopresti AL. Curcumin and piperine supplementation on reducing pain and improving physical function in participants with moderate to severe knee osteoarthritis. Clin Interv Aging. 2023;18:1223-1235. doi:10.2147/CIA.S413970
124. Prasad S, Aggarwal BB. Curcumin for reducing side effects of chemotherapy and radiotherapy. Phytother Res. 2021;35(3):1355-1369. doi:10.1002/ptr.6925
125. Safari S, Rahmati B, Tavalaei S, et al. Curcumin effects on chronic obstructive pulmonary disease: A systematic review. Health Sci Rep. 2023;6(3):e1162. doi:10.1002/hsr2.1162
126. Zeng Y, Hong H, Guo Y, et al. Therapeutic effect of curcumin on metabolic diseases. Nutrients. 2023;12(2):476. doi:10.3390/nu12020476
127. Mills S, Bone K. Turmeric (Curcuma longa)-Anti-inflammatory and antimicrobial actions. In: Principles and Practice of Phytotherapy. 1st ed. Edinburgh: Churchill Livingstone; 2000. p. 483-491. doi:10.1016/S0006-2952(98)00114-2
128. Hellmann PW, Weickert MO, Eur C, et al. No effect of the turmeric root phenol curcumin on insulin-induced weight gain and hepatic steatosis: A randomized, double blind, placebo-controlled trial. Nutrients. 2023;12(4):987. doi:10.3390/nu12040987
129. Sedighi S, Eslamian G, Mazidi M, et al. The effects of curcumin supplementation on inflammatory biomarkers in patients with systemic lupus erythematosus. Phytother Res. 2024;38(11):5845-5854. doi:10.1002/ptr.8123
130. Panahi Y, Saeedi M, Akbari H, et al. Curcumin supplementation in kidney transplant recipients: A randomized controlled trial. World J Gastroenterol. 2022;28(42):6135-6149. doi:10.3748/wjg.v28.i42.6135
131. Ashrafizadeh M, Ahmadi Z, Mohammadinejad R, et al. Curcumin in metabolic health and disease. Nutrients. 2021;14(3):520. doi:10.3390/nu14030520
132. Besasie BD, Saha A, DiGiovanni J, Liss MA. Effects of curcumin and ursolic acid in prostate cancer: A systematic review. Prostate Cancer Prostatic Dis. 2024;27(1):66-79. doi:10.1177/03915603231202304
133. Prasad S, Tyagi AK, Aggarwal BB. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: The golden pigment from golden spice. J Pharm Pharmacol. 2014;66(4):490-503. doi:10.1111/jphp.12313
134. Brace LD. Impact of curcumin on cardiovascular and metabolic diseases: Preclinical and clinical updates. J Cardiovasc Pharmacol Ther. 2016;21(4):350-362. doi:10.1177/1074248416638964
135. Wei F, Yang H, Zhang H. Curcuma longa and COVID-19: Evidence-based perspectives. J Ethnopharmacol. 2020;259:112978. doi:10.1016/j.jep.2020.112978
136. Al-Dujaili EA, Smail N. Pomegranate juice intake enhances salivary testosterone levels and improves mood and well being in healthy men. Endocr Abstr. 2012;28:313.
137. Singh RG, Dey U, Dey R, et al. Advances in curcumin bioavailability: Effects of novel formulations. J Funct Foods. 2024;112:105625. doi:10.1016/j.jff.2024.105625
138. Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: Lessons learned from clinical trials. AAPS J. 2013;15(1):195-218. doi:10.1208/s12248-012-9432-
139. Sethi V, Garg M, Herve M, Mobasheri A. Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis. Ther Adv Musculoskelet Dis. 2022;14:1759720X221124545. doi:10.1177/1759720X221124545
140. Koshikumar A, Jayaprakash A, Aswathy BS, et al. Synergistic anti-inflammatory activity of ginger and turmeric extracts in lipopolysaccharide and interferon-γ-induced murine RAW 264.7 cells. Front Pharmacol. 2022;13:818166. doi:10.3389/fphar.2022.818166
141. Prasad S, Aggarwal BB. Curcumin: Target for signals transduction, transcription factors, and genes implicated in various disorders. Curr Med Chem. 2020;13(16):1891-900. doi:10.2174/0929867067774489
142. Srimal RC, Dhawan BN. Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent. J Pharm Pharmacol. 2000;25(6):447-452. doi:10.1111/j.2042-7158.1973.tb09131.x
143. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005;50(11):2191-2193. doi:10.1007/s10620-005-3032-8
144. Araujo CC, Leon LL. Biological activities of Curcuma longa L. Mem Inst Oswaldo Cruz. 2001;96(5):723-728. doi:10.1590/S0074-02762001000500026
145. Reddy AC, Lokesh BR. Studies on spice principles as antioxidants in the inhibition of lipid peroxidation of rat liver microsomes. Mol Cell Biochem. 1992;111(1-2):117-124. doi:10.1007/BF00229582
146. Patel M, Mehta V. Recent clinical evidence for turmeric and curcumin in managing COVID-19. Phytother Res. 2025;39(1):123-129. doi:10.1002/ptr.7662
147. Pari L, Murugan P. Protective role of tetrahydrocurcumin against erythromycin estolate-induced hepatotoxicity. Pharmacol Res. 2004;49(5):481-486. doi:10.1016/j.phrs.2003.11.005
148. Nirmala C, Puvanakrishnan R. Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol Cell Biochem. 1996;159(2):85-93. doi:10.1007/BF00420910
149. Thapliyal R, Maru GB. Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem Toxicol. 2001;39(6):541-547. doi:10.1016/S0278-6915(00)00165-4
150. Rani K, Satapathy S, Panda S, et al. Curcumin and its nanoformulations in infectious diseases: New avenues for old remedies. J Nanomed Nanotechnol. 2022;13(5):1-10. doi:10.35248/2157-7439.22.13.644
151. Kunnumakkara AB, Bordoloi D, Harsha C, et al. Curcumin, the golden nutraceutical: Multitargeting for multiple chronic diseases. Br J Pharmacol. 2017;174(11):1325-1348. doi:10.1111/bph.13621
152. Lin L, Hu K, Gao Y, et al. Bioactivities of EF24, a novel curcumin analog: A review. Front Oncol. 2018;8:614. doi:10.3389/fonc.2018.00614
153. Jourghanian P, Ghaffari S, Ardjmand M, et al. Sustained release curcumin loaded solid lipid nanoparticles. Int J Pharm. 2016;511(1):406-419. doi:10.1016/j.ijpharm.2016.07.013
154. Zarei M, Aghaei A, Sedighi S, et al. Synergistic effects of metformin and curcumin on gastric cancer cell apoptosis. EXCLI J. 2021;20:1488-1498. doi:10.17179/excli2021-4091
155. Shoba G, Joy D, Joseph T, et al. Bioavailability enhancers of herbal origin: An overview. J Med Food. 2013;16(2):101-111. doi:10.1089/jmf.2012.2276
156. Karthikeyan A, Senthil N, Min T. Nanocurcumin: A promising candidate for therapeutic applications. Molecules. 2020;25(8):1739. doi:10.3390/molecules25081739
157. Han Y, Peng S, Liu Z, et al. Innovative delivery systems for curcumin: Exploring nanosized and advanced formulations. Pharmaceuticals. 2024;17(5):671. doi:10.3390/ph17050671
158. Bahrami H, Alikhani Z, Rahmani D, et al. Molecular docking and in silico screening of  novel curcumin derivatives targeting NF-κB and STAT3 pathways. Pharmaceuticals. 2024;17(5):614. doi:10.3390/ph17050614
159. Jamshed H, Hasan AU, Poudyal H, et al. The synergistic and anticancer potential of Withania somnifera (Ashwagandha) and its active components in combination therapy. J Integr Med. 2024;22(4):e1054. doi:10.1016/j.joim.2024.04.005
160. Cecchin E, Stocco G. Pharmacogenomics and personalized medicine. Genes (Basel). 2020;11(6):679. doi:10.3390/genes11060679
161. Murtaza H, Ahmed S, Khan MA, et al. Green synthesized (Curcuma longa) Ni nanoparticles doped chitosan and PEG for wound healing and anti-bacterial activity. Int J Biol Macromol. 2025;259:129847. doi:10.1016/j.ijbiomac.2025.129847
162. Xie W, Wu L, He Z. Recent updates on the pharmacokinetics of curcumin: Approaches to overcome challenges. Expert Opin Drug Metab Toxicol. 2021;17(8):911-926. doi:10.1080/17425255.2021.1956089
163. Verma N, Kumari R, Yadav D. Synergistic effects of turmeric and conventional drugs in clinical management of cancer. Curr Drug Targets. 2022;23(9):873-882. doi:10.2174/1389450123666220506102323
164. Tripathi S, Sahoo A, Rath S, et al. Curcumin and metabolic syndrome: Ongoing updates from recent research. Nutrients. 2023;15(11):2212. doi:10.3390/nu15112212
165. Barreto RS, Quintans-Junior LJ, Saavedra LM, et al. Therapeutic potential of turmeric in age-related disorders: A translational review. Ageing Res Rev. 2020;63:101135. doi:10.1016/j.arr.2020.101135